Cytheris SA, an Issy Les Moulineaux, France-based biopharmaceutical company focused on R&D of new drugs for immune modulation, has closed a €12m (approximately $15m) Series D funding round.
The syndicate of investors include international operators such as new venture partner CDC Entreprises, acting on behalf of the Strategic Investment Fund (FSI), and existing backers Bioam Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity, and Forbion Capital Partners.
As a part of the financing, Marie-Laure Garrigues, Director of Investments at CDC Entreprises, will become an observer of the company’s board of directors.
The new capital will enable Cytheris to accelerate development of the interleukin-7 (CYT107) clinical programs. Recombinant human IL-7 (CYT107) is a critical immune-modulator for immune T-cell recovery.
The company is conducting international investigations of IL-7 in Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), idiopathic CD4 lymphocytopenia and cancer.
Cytheris also operates a U.S. subsidiary in Rockville, Maryland.
FinSMEs
07/06/2010